This week take a look at a new, long-acting, adhesive for your pesky medical devices, a report by Medscape finding that Doctors are more burnt out now than ever before, improved limits for lead in baby food, and other top news!
Adhesive for your medical devices
3M has launched a new adhesive line that has doubled the time a person with a medical device can wear one. 2 weeks has been the standard time an adhesive for a medical device usually lasts, but not anymore. 3M first introduced an adhesive tape to keep devices on for 3 weeks, but the company decided to one-up even themselves with their latest product; 3M Medical Tape 4578 which can keep health sensors/monitors on for up to 28 days. Read more here.
Burnout & Depression affect Doctors more than ever
A Medscape report has found Doctor burnout to be higher than it has ever been before, even as the effects of the COVID-19 pandemic begin to mitigate. The report was based on a survey of over 9000 physicians across the country, conducted in 2022. The report shows not only high levels of burnout among doctors but also high incidences of depression, which is a serious concern. Read more about the report here.
Eli Lilly’s lymphoma therapy granted fast approval
Eli Lilly’s Jaypirca has been granted fast approval by the FDA as a therapy for mantle cell lymphoma. The treatment was approved for patients who have already received other therapies with no success. The price tag for the therapy may be considered hefty, with pricing for a month supply at $21,000.
The company announced that the drug, which will be sold under the name Jaypirca, will soon be available in the U.S. According to a Lilly representative, the list price for a 30-day supply of Jaypirca at the Indianapolis pharmaceutical company is $21,000. Jaypirca can be used even if other BTK inhibitors have failed, since it is a different type of inhibitor. To read more about the therapy, click here.
New limits for lead in baby food
The FDA is suggesting new limits on the quantity of lead that can be in baby food for children under the ages of two. The new limits hope to prevent the harmful effects lead has on the development of children. These limits will decrease lead exposure by 27%. The FDA, however, cannot enforce companies producing baby food to comply with these limits as they are not legally binding. To read more about this, click here.
Teva to expand into the injectable Schizophrenia market, joining others
Teva has begun phase 3 of its clinical trial assessing an injectable & long-acting schizophrenia drug. Teva’s therapy is based on the same active ingredient as Eli Lilly’s therapy, which has been on the market for decades now but there have been some concerns with its safety in the past. J&J and Luye have their own injectable therapy for the difficult illness as well. To read more about the trial, click here.
Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.